Tesaro's Zejula Expansion Includes Keytruda Combo, Lung Cancer
The company, encouraged by positive Phase I data from a trial testing the PARP inhibitor niraparib in combination with Merck's PD-1 inhibitor Keytruda in recurrent ovarian cancer, plans to initiate a larger trial by the end of the year or early in 2018.
You may also be interested in...
Ovarian Cancer Pipeline Review: Sponsors Plan Frontline Punch, Smart Combinations
Combination studies of drugs for ovarian cancer have heavy focus on PARP, PD-1/L1 and VEGF mechanisms.
Deal Watch: Fresenius Buyout Of Akorn Potentially Threatened By Data Integrity Issues
AstraZeneca takes second license of antisense candidate under 2012 pact with Ionis, this time for kidney disease. Aldeyra is working with J&J on novel immune-modulating drugs for systemic inflammatory conditions.
PARP Inhibitors: Rich Prospects And More Deals In Store?
There’s significant excitement around the potential of PARP inhibitors in the currently established indication of ovarian cancer, but the best is probably yet to come with expansion into other cancers, according to a biopharma advisory firm. This class of drugs is also expected to trigger M&A, putting the spotlight on firms like Tesaro and Clovis Oncology.